TREMFYA Approved for Moderately to Severely Active Ulcerative Colitis
Johnson & Johnson announced that the FDA has approved TREMFYA (guselkumab) for treating adults with moderately to severely active ulcerative colitis. TREMFYA is the first fully human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting a key cytokine driving UC and other immune-mediated diseases.
“Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining,” said Dr. David T. Rubin, Director of the Inflammatory Bowel Disease Center a...
